TY - JOUR T1 - Contemporary trends in use of mechanical circulatory support in patients with acute MI and cardiogenic shock JF - Open Heart JO - Open Heart DO - 10.1136/openhrt-2019-001214 VL - 7 IS - 1 SP - e001214 AU - Ole Kristian Lerche Helgestad AU - Jakob Josiassen AU - Christian Hassager AU - Lisette Okkels Jensen AU - Lene Holmvang AU - Nanna Louise Junker Udesen AU - Henrik Schmidt AU - Hanne Berg Ravn AU - Jacob Eifer Moller Y1 - 2020/03/01 UR - http://openheart.bmj.com/content/7/1/e001214.abstract N2 - Objectives To describe the contemporary trends in the use of mechanical circulatory support (MCS) in patients with acute myocardial infarction and cardiogenic shock (AMICS). To evaluate survival benefit with early application of intra-aortic balloon pump (IABP) or Impella CP.Methods A cohort study of all consecutive patients with AMICS undergoing percutaneous coronary intervention (PCI) <24 hours of symptom onset (early PCI) in southeastern Denmark from 2010 to 2017. A matched case–control study comparing 30-day mortality between patients receiving early-IABP or early-Impella CP and their respective control group. Controls were matched on age, left ventricular ejection fraction, arterial lactate, estimated glomerular filtration rate and cardiac arrest before PCI. Early-IABP/Impella CP was defined as applied before PCI if shock developed pre-PCI, or immediately after PCI if shock developed during PCI.Results 903 patients with AMICS undergoing early PCI were identified. Use of MCS decreased from 50% in 2010 to 25% in 2017, p for trend of <0.001. The IABP was abandoned in 2012 and replaced mostly by Impella CP. Patients receiving MCS in 2013–2017 had more compromised haemodynamics compared with patients receiving MCS in 2010–2012. 40 patients received early IABP, and 40 patients received early Impella CP. Only the group receiving early Impella CP was associated with lower 30-day mortality compared with their matched control group (30-day mortality 40% vs 77.5%, plog-rank of<0.001).Conclusion Use of MCS decreased by 50% from 2010 to 2017. Patients receiving MCS had more compromised haemodynamics in recent years. Early application of Impella CP was associated with reduced 30-day mortality compared with a matched control group. ER -